Loading
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
Previous close
$7.18
+$0.40 · +5.90%
After-hours
$7.07
−$0.11 · -1.53%
Oct 9, 7:30 PM ET
Regular session · ET · Market data may be delayed.
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
Day range
Current $7.18
52-week range
Current $7.18
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
45
Fair Value
Sentiment
45
Mixed
Risk
75
High Risk
Momentum
20
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
Day range
Current $7.18
52-week range
Current $7.18
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 2.19M USD | — | — | — | — |
| Gross profit | −2.19M USD | — | — | — | — |
| Research and development | 44.92M USD | 41.49M USD | 47.93M USD | 54.2M USD | 50.19M USD |
| Selling, general, and administrative | 12.69M USD | 15.72M USD | 19.71M USD | 21.71M USD | 20.57M USD |
| Operating expenses | 55.43M USD | 59.75M USD | 67.64M USD | 75.91M USD | 70.77M USD |
| Interest income | — | — | — | 1.17M USD | 1.32K USD |
| Interest expense | — | — | — | — | 77K USD |
| Depreciation and amortization | 2.19M USD | 2.87M USD | 3.68M USD | 4.12M USD | 4.18M USD |
| Operating income | −57.62M USD | −59.75M USD | −67.64M USD | −75.91M USD | −70.77M USD |
| Net income | −55.84M USD | −55.65M USD | −62.72M USD | −74.73M USD | −69.39M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI787.73K0.00%2.3T USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF214.49K0.00%95.4B USD0.05%$235+0.80%
iShares Micro-Cap ETFIWC76.87K0.01%1.32B USD0.60%$183+0.11%
U.S. Micro Cap Portfolio ETFDFMC18.37K0.00%7.56B USD0.43%$57.813+0.20%
Dimensional - US Core Equity 2 ETFDFAC400.020.00%88.6B USD0.21%$45.33+0.49%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCDimensional - US Core Equity 2 ETFDFACAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
